Browse > Article

Clinical Factors Associated with Recurrence of Nasopharyngeal Carcinoma  

Ok, Sohea (Department of Otorhinolaryngology-Head and Neck Surgery, Korea University College of Medicine)
Lee, Soo-Hyung (Department of Otorhinolaryngology-Head and Neck Surgery, Korea University College of Medicine)
Hwang, Sunjin (Department of Otorhinolaryngology-Head and Neck Surgery, Korea University College of Medicine)
Park, Min-Woo (Department of Otorhinolaryngology-Head and Neck Surgery, Korea University College of Medicine)
Cho, Jae-Gu (Department of Otorhinolaryngology-Head and Neck Surgery, Korea University College of Medicine)
Baek, Seung-Kuk (Department of Otorhinolaryngology-Head and Neck Surgery, Korea University College of Medicine)
Kwon, Soon-Young (Department of Otorhinolaryngology-Head and Neck Surgery, Korea University College of Medicine)
Jung, Kwang-Yoon (Department of Otorhinolaryngology-Head and Neck Surgery, Korea University College of Medicine)
Woo, Jeong-Soo (Department of Otorhinolaryngology-Head and Neck Surgery, Korea University College of Medicine)
Publication Information
Korean Journal of Head & Neck Oncology / v.30, no.1, 2014 , pp. 5-9 More about this Journal
Abstract
Background and Objectives : The objective of this study was to investigate clinical factors associated with recurrence of nasopharyngeal carcinoma(NPC). Materials and Methods : We performed a retrospective review of 112 diagnosed as nasopharyngeal carcinoma, treated concurrent chemo-radiotherapy(CCRT) and had complete response from March 1, 1995, to March 31, 2012. Results : Of the recurrent NPC patients, patients received 2nd line chemotherapy had more recurrence within 2 years(p=0.010). Especially, patients received 2nd line chemotherapy longer than 4 months tend to have recurrence early(p=0.035). Other factors are not different between recurrent and non-recurrent NPC patients. Conclusion : The presence and the duration of 2nd line chemotherapy are associated with early recurrence.
Keywords
Nasopharyngeal carcinoma; Recurrence; Clinical factor;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Yeh SA, Tang Y, Lui CC, Huang YJ, Huang EY. Treatment outcomes and late complications of 849 patients with nasopharyngeal carcinoma treated with radiotherapy alone. Int J Radiat Oncol Biol Phys. 2005;62(3):672-679.   DOI   ScienceOn
2 Li JX, Lu TX, Huang Y, Han F. Clinical characteristics of recurrent nasopharyngeal carcinoma in high-incidence area. ScientificWorldJournal [719754] 2012 [cited 2012 Feb 1];1(1):[8 screens]. Available from: URL: http://www.hindawi.com/ journals/tswl /2012/719754/eid.htm.
3 Chan JY, Chow VL, Wong ST, Wei WI. Surgical salvage for recurrent retropharyngeal lymph node metastasis in nasopharyngeal carcinoma. Wiley Inter Science [23214] 2013 [cited 2013 Mar 6];1(1):[6 screens]. Available from: URL: http://www. wileyonlinelibrary.com/eid.htm.
4 Chua DT, Sham JS, Kwong DL, Wei WI, Au GK, Choy D. Locally recurrent nasopharyngeal carcinoma: Treatment results for patients with computed tomography assessment. Int J Radiat Oncol Biol Phys. 1998;41(2):379-386.   DOI   ScienceOn
5 Lee AWM, Law SCK, Foo W, Poon YF, Cheung FK, Chan DK, et al. Retrospective analysis of patients with nasopharyngeal carcinoma treated during 1976-1985: Survival after local recurrence. Int J Radiat Oncol Biol Phys. 1993;26:773-782.   DOI   ScienceOn
6 Pazdur R, Wagman L, Camphausen K, Hoskins W. Cancer Management: A Multidisciplinary Approach. 12th ed. Norwalk, Conn: CMP Healthcare Media LLC; 2009.
7 National Comprehensive Cancer Network. National Comprehensive Cancer Network Guidelines. Head and Neck Cancers V 1.2012. [cited 2013 May 12]. Available from: URL: http://www. nccn.org.
8 Glisson BS, Murphy BA, Frenette G, Khuri FR, Forastiere AA. Phase II Trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck. J Clin Oncol. 2002;20(6):1593-1602.   DOI   ScienceOn
9 Samlowski WE, Moon J, Kuebler JP, Nichols CR, Gandara DR, Ozer H, et al. Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck(SCCHN): A Southwest Oncology Group Phase II study. Cancer Invest. 2007;25(3):182-190.   DOI
10 Tan EH, Khoo KS, Wee J, Fong KW, Lee KS, Lee KM, et al. Phase II trial of a paclitaxel and carboplatin combination in Asian patients with metastatic nasopharyngeal carcinoma. Ann Oncol. 1999;10(2):235-242.   DOI
11 Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized Intergroup study 0099. J Clin Oncol. 1998;16(4):1310-1317.
12 Lee AW, Lau WH, Tung SY, Chua DT, Chappell R, Xu L, et al. Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group. J Clin Oncol. 2005;23(28):6966- 6975.   DOI   ScienceOn
13 Gibson MK, Li Y, Murphy B, Hussain MH, DeConti RC, Ensley J, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer(E1395): An intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2005;23(15):3562-3569.   DOI
14 Lee AW, Sze WM, Au JS, Leung SF, Leung TW, Chua DT, et al. Treatment results for nasopharyngeal carcinoma in the modern era: The Hong Kong experience. Int J Radiat Oncol Biol Phys. 2005;61(4):1107-1118.   DOI   ScienceOn